Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-24-081588
Filing Date
2024-09-25
Accepted
2024-09-25 08:13:08
Documents
3
Period of Report
2024-09-25

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0215301-6k_nlspharma.htm 6-K 15202
2 AMENDED AND RESTATED ARTICLES OF ASSOCIATION ea021530101ex99-1_nlspharma.htm EX-99.1 210687
3 PRESS RELEASE TITLED: "NLS PHARMACEUTICS LTD. ANNOUNCES EXPECTED IMPLEMENTATION ea021530101ex99-2_nlspharma.htm EX-99.2 7942
  Complete submission text file 0001213900-24-081588.txt   234875
Mailing Address THE CIRCLE 6 8058 ZURICH V8 CH-6370
Business Address THE CIRCLE 6 8058 ZURICH V8 CH-6370 41-41-618-80-00
NLS Pharmaceutics Ltd. (Filer) CIK: 0001783036 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39957 | Film No.: 241321376
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)